Nippon Biologicals Inc

Nippon Biologicals, Inc. (NBI) currently holds 15 avian biological licenses from MAFF. NBI is expected to receive one additional license by December 31, 2007, for a total to 16 avian biological licenses from MAFF. In terms of number of avian biological licenses, this puts NBI into first position amongst the 16 vaccine companies operating in Japan. We anticipate four additional biological licenses to be registered by December 31, 2008, placing NBI far ahead of any avian biological company in Japan.

Of the 16 vaccine companies, NBI is the only company focused on avian biologicals. It is also the only company with a clear vision and straightforward message to the avian market. NBI is a step ahead of competitors because NBI understands both the chicken business and the science of avian biologicals. Whilst the competitors are occupied in supplying the “wants” of the poultry industry (making vaccines as diseases occur) NBI tries to anticipate the “needs” (deliver the best biological solutions). Our First Phase prime vaccines focus on live bacteria (MG, MS). The message to the market is: Tender-Loving-Care Vaccine, or no-stress vaccine. Our Second Phase prime vaccines focus on poultry disease prevention linked to food poisoning (salmonella, E. coli etc.). The message to the market is: Food Safety Generating Vaccine.

Based on the vision established by NBI, vaccines in registration for the First Phase (1994-2000) are all live vaccines whenever possible, and aluminum hydroxide adjuvant inactivated vaccines when live is not technically possible. The benefits of our vision to the poultry industry are clear and beneficial - less but more effective vaccination and reduced stress to birds resulting in higher productivity.

In 2005 NBI established an Overseas Division with the strategic objective of exporting innovative animal health products discovered and developed in Japan to the global markets. The strategic objective is to build a platform for; Japan discovered innovative products for commercialization in the important markets outside of Japan. NBI Overseas Division has obtained global marketing rights for Nisseiken's swine vaccine APM777. This unique inactivated vaccine is the first to multivalent vaccine combining antigens for Mycoplasma hyopneumoniae with 3 strains of Actinobacillus pleuropneumoniae; included are 3 types of non-toxigenic cytotoxins of APP derived from recombinant E. coli. Product registrations are currently in process in 8 countries. Two additional products are in process to be placed on the platform for commercialization.

NBI operates on efficiency. With only 8 employees inclusive of the CEO and a secretary, it is capable of registering about 4 products per year and operates & manages a vaccine quality control laboratory, as well as, shipping & inventory control. The nearest competitor with only 4 products has 22 employees. The Japanese biological industry average is approximate 4 employees per product. Therefore, NBI is at least 10 times more efficient than the average biological company.

Mg live vaccine
MS live vaccine
NB live vaccine
AE vaccine
MD / HVT live vaccine
MD / CVI live vaccine
MD / HVT + SB-1 vaccine